Summary: New research shows that a mutation linked to Alzheimer’s disease disrupts the production and quality of exosomes — tiny extracellular vesicles that neurons and brain immune cells use to communicate. Cells carrying a defective SORLA protein released roughly 30% fewer exosomes, and those exosomes were as much as 50% less effective at supporting the growth and maturation of neighboring cells.
This compromised intercellular communication may accelerate Alzheimer’s progression by weakening the brain’s ability to maintain healthy neural networks and tissue. The findings point to therapeutic opportunities aimed at restoring exosome release or improving exosome content and function.
Key Facts
- SORLA mutation: Associated with about 30% fewer exosomes produced by affected cells.
- Reduced support: Exosomes from mutant cells were up to 50% less effective at promoting neighboring cell growth and maturation.
- Therapeutic potential: Strategies that boost exosome biogenesis or enhance exosome cargo could provide new approaches to treat Alzheimer’s disease.
Source: Aarhus University
Tiny particles with major implications
Researchers at the Department of Biomedicine, Aarhus University, have discovered that a genetic change connected to familial Alzheimer’s disease interferes with the generation and neurotrophic quality of exosomes. These findings improve our understanding of mechanisms that may contribute to Alzheimer’s and suggest new directions for treatment development.
Exosomes are extremely small membrane-bound vesicles — so tiny that millions can fit on the tip of a rice grain — yet they carry proteins, RNAs and signaling molecules that shape cell-to-cell communication in the brain. The new study, led in part by Assistant Professor Kristian Juul-Madsen, was published in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
SORL1 is one of four major genes linked to inherited forms of Alzheimer’s disease. SORL1 encodes the sorting receptor SORLA, a protein involved in intracellular trafficking. The team focused on a specific mutation, SORLA N1358S, located in the receptor’s ligand-binding domain, to better understand how SORLA supports brain cell health.
The researchers found that cells expressing the mutated SORLA produced about 30% fewer exosomes. Moreover, the exosomes that were released had diminished neurotrophic activity — they were up to 50% less effective at stimulating the growth and maturation of neighboring neurons and supporting cells compared with exosomes from cells with normal SORLA.
This functional decline in exosome-mediated signaling likely undermines essential support processes in the brain. According to the authors, exosomes from microglia and other brain cells play a central role in maintaining neuronal health and connectivity, and impaired exosome release or altered exosome cargo could be a contributing factor to Alzheimer’s pathology in people who carry SORL1 variants.
Kristian Juul-Madsen notes that the discovery opens clear avenues for therapeutic exploration. Potential strategies include boosting SORLA function to increase exosome production and quality or modulating other receptors and pathways known to enhance exosome biogenesis. Such interventions might restore healthier intercellular communication in the aging or diseased brain.
Alzheimer’s disease is the most common age-related dementia in Denmark, affecting an estimated 55,000 people. Despite extensive research, effective disease-modifying treatments remain elusive, underscoring the importance of novel mechanistic insights like those provided by this study.
Behind the research – more information
- Study type: Basic laboratory research using induced pluripotent stem cells (iPSCs). The investigators generated iPSC-derived human neurons and microglia that carry the disease-associated SORL1 mutation and compared them to genetically matched control cells. The work also included broad “omics” analyses to profile the protein and RNA content of exosomes.
- Collaborators: The project was conducted as an LF Postdoc project with work performed in Thomas Willnow’s laboratories at the Max Delbrück Center for Molecular Medicine in Berlin and at the Department of Biomedicine, Aarhus University.
- External funding: Funding came mainly from a Lundbeck Foundation LF postdoctoral grant (R380-2021-1326) awarded to Kristian Juul-Madsen, as well as support from a Novo Nordisk Foundation Laureate grant (NNF18OC0033928) and a research grant from the Alzheimer Forschung Initiative (18003) awarded to Prof. Thomas Willnow.
- Potential conflicts of interest: None declared.
About this Alzheimer’s disease research news
Author: Vibe Noordeloos
Source: Aarhus University
Contact: Vibe Noordeloos – Aarhus University
Image: The image is credited to Neuroscience News
Original Research: Open access. “Familial Alzheimer’s disease mutation identifies novel role of SORLA in release of neurotrophic exosomes” by Kristian Juul-Madsen et al., Alzheimer’s & Dementia
Abstract
Familial Alzheimer’s disease mutation identifies novel role of SORLA in release of neurotrophic exosomes
INTRODUCTION
Mutations in SORL1, which encodes the sorting receptor SORLA, have been identified in individuals with Alzheimer’s disease. The study examined the SORLA N1358S variant, which alters the receptor’s ligand-binding domain, to explore receptor functions that affect human brain health.
METHODS
The authors evaluated the effects of SORLA N1358S expression in iPSC-derived human neurons and microglia using unbiased proteomic screens and functional cell assays to characterize exosome release and activity.
RESULTS
The study revealed changes in the SORLA N1358S interactome related to exosome biogenesis. The mutant receptor failed to promote normal exosome release and impaired the neurotrophic properties of the vesicles, a defect linked to altered microRNA content within exosomes that influence neuronal maturation.
DISCUSSION
These results implicate SORLA in controlling both the quantity and neurotrophic quality of exosomes secreted by brain cells. Impaired exosome-mediated communication may represent a pathological mechanism contributing to Alzheimer’s disease in carriers of SORL1 variants.
Highlights
- Familial Alzheimer’s mutation in SORL1 alters the interactome of the SORLA receptor.
- Mutant SORLA reduces exosome release from neurons and microglia.
- Exosomes derived from mutant cells lack normal neurotrophic qualities.
- Defects correlate with changes in exosomal microRNA content that control neuronal maturation.